MedTrace Logo

Gene Polymorphism of IL17 and IL 23

NCT04948515 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-10-25

No results posted yet for this study

Summary

rates are in such considerable amount among large population base. The pathogenesis of COVID-19 implicates a potent inflammatory response, involving a complex group of mediators including interleukins. These pleiotropic cytokines are secreted at the region of inflammation and released into the circulation by a variety of different cell types, including macrophages, lymphocytes, endothelial cells, epithelial cells during sepsis and acute organ injuries. There has recently found a number of studies reporting that the cytokine storms take part in the course of COVID-19

Conditions

  • COVID-19 Respiratory Infection

Interventions

DIAGNOSTIC_TEST

laboratory test

genotyping of IL 17 and IL23

DIAGNOSTIC_TEST

laboratory test

estimation of serum level of IL 17

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • N S shafik, lecturer · Sohag University

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-03
Primary Completion
2021-11-30
Completion
2021-12-03

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04948515 on ClinicalTrials.gov